Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Premature Ejaculation-Pipeline Review, H1 2015

Premature Ejaculation-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Premature Ejaculation-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Premature Ejaculation-Pipeline Review, H1 2015', provides an overview of the Premature Ejaculation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Premature Ejaculation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Premature Ejaculation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Premature Ejaculation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Premature Ejaculation Overview 6

Therapeutics Development 7

Pipeline Products for Premature Ejaculation-Overview 7

Pipeline Products for Premature Ejaculation-Comparative Analysis 8

Premature Ejaculation-Therapeutics under Development by Companies 9

Premature Ejaculation-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Premature Ejaculation-Products under Development by Companies 13

Premature Ejaculation-Companies Involved in Therapeutics Development 14

Actavis plc 14

Dong-A Socio Group 15

NeuroHealing Pharmaceuticals Inc. 16

Plethora Solutions Holdings plc 17

SK Chemicals Co., Ltd. 18

Yungjin Pharm Ind. Co., Ltd. 19

Premature Ejaculation-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Combination Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

(lidocaine + prilocaine)-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

DA-8031-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

IX-01-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

modafinil-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

NCE-405-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

onabotulinumtoxin A-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

tramadol hydrochloride-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

YPE-1706-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Premature Ejaculation-Recent Pipeline Updates 42

Premature Ejaculation-Dormant Projects 48

Premature Ejaculation-Discontinued Products 50

Premature Ejaculation-Product Development Milestones 51

Featured News & Press Releases 51

Jan 08, 2015: Vyrix Pharmaceuticals to Present at Biotech Showcase 2015 51

Nov 11, 2014: Plethora Solutions Provides Company Update 51

Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU 52

Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment 53

Mar 11, 2014: Plethora Solutions Provides Company update 53

Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation 54

Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation 54

Jul 01, 2013: AGM Statement & PSD502 Regulatory Update 55

Jun 03, 2013: Ampio Pharma Provides Update On Sexual Dysfunction Portfolio 55

Mar 11, 2013: Ampio Receives FDA Acceptance Of Patient Outcome For Premature Ejaculation Questionnaire Paving Way For US Pivotal Trial On Zertane 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

Number of Products under Development for Premature Ejaculation, H1 2015 7

Number of Products under Development for Premature Ejaculation-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Premature Ejaculation-Pipeline by Actavis plc, H1 2015 14

Premature Ejaculation-Pipeline by Dong-A Socio Group, H1 2015 15

Premature Ejaculation-Pipeline by NeuroHealing Pharmaceuticals Inc., H1 2015 16

Premature Ejaculation-Pipeline by Plethora Solutions Holdings plc, H1 2015 17

Premature Ejaculation-Pipeline by SK Chemicals Co., Ltd., H1 2015 18

Premature Ejaculation-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Assessment by Combination Products, H1 2015 21

Number of Products by Stage and Target, H1 2015 23

Number of Products by Stage and Mechanism of Action, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Premature Ejaculation Therapeutics-Recent Pipeline Updates, H1 2015 42

Premature Ejaculation-Dormant Projects, H1 2015 48

Premature Ejaculation-Dormant Projects (Contd..1), H1 2015 49

Premature Ejaculation-Discontinued Products, H1 2015 50

List of Figures

Number of Products under Development for Premature Ejaculation, H1 2015 7

Number of Products under Development for Premature Ejaculation-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Targets, H1 2015 22

Number of Products by Stage and Top 10 Targets, H1 2015 23

Number of Products by Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis plc

Dong-A Socio Group

NeuroHealing Pharmaceuticals Inc.

Plethora Solutions Holdings plc

SK Chemicals Co., Ltd.

Yungjin Pharm Ind. Co., Ltd.

Premature Ejaculation Therapeutic Products under Development, Key Players in Premature Ejaculation Therapeutics, Premature Ejaculation Pipeline Overview, Premature Ejaculation Pipeline, Premature Ejaculation Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com